Advyzom is a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for our partners in the pharmaceutical and healthcare industry.
Arch Bipartners Selects D3 Medicine and Advyzom to develop Human Clinical Trial and Regulatory Strategy for Brain Tumor Targeting Technology
My 29, 2014
Arch Biopartners announced today it has selected d3 Medicine to work as the Company's new drug development team. Advyzom will provide the regulatory strategy for the program. The team's first task will be to design a Phase I/II human trial for MetaMx, the Company's brain tumour targeting technology, in patients with malignant glioma. For more information, click here